NCT07296705 2025-12-22
HARBOR
Fujian Medical University Union Hospital
Phase 2 Recruiting
Clinical Trials
15 trialsNCT05189457 2025-12-04
First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Active not recruiting
NCT06866548 2025-12-04
Safety and Efficacy Evaluation of Anti IGF-1R Monoclonal Antibody Combined With Anti-PD-1 Monoclonal Antibody in Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer
Shanghai Changzheng Hospital
Phase EARLY_PHASE1 Active not recruiting
NCT07233252 2025-11-18
Nephron-sparing Treatment of Tislelizumab + Nab-Paclitaxel for Renal Pelvic Cancer
Tianjin Medical University Second Hospital
Phase 2 Recruiting
NCT06916494 2025-04-10
Pilot Study on Rutin Combined With Tislelizumab and GC (Gemcitabine and Cisplatin) as Neoadjuvant Therapy for Platinum-refractory Muscle-invasive Bladder Cancer
First Affiliated Hospital of Chongqing Medical University
Phase 1 Recruiting
NCT05531123 2024-07-12
Risk-stratification Based Bladder-sparing Modalities for Muscle-invasive Bladder Cancer
Fudan University
Phase 2 Recruiting
NCT06441110 2024-06-04
Multicenter Clinical Trial on the Effectiveness and Safety of Instillation of BCG and Alternative BCG Protocols for Intermediate and High-risk Non-muscle Invasive Bladder Cancer
Fujian Medical University Union Hospital
Phase 3 Recruiting
NCT06387056 2024-04-26
SEGNO
The First Affiliated Hospital of Xiamen University
Phase 2 Recruiting
NCT06211790 2024-01-18
Proteomic Guided First-line Precision Treatment of Renal Clear Cell Carcinoma
Fudan University
Phase 2 Recruiting
NCT05957757 2023-08-31
RC48 Combined With Tislelizumab for Bladder Sparing Treatment in NMIBC With BCG Treatment Failure and HER2 Expression
RenJi Hospital
Phase 2 Recruiting
NCT05445648 2022-12-28
CBPTMI
First Affiliated Hospital Xi'an Jiaotong University
Phase 2 Unknown
NCT04730219 2022-11-30
Perioperative Tislelizumab Combined With Nab-Paclitaxel for Muscle-invasive Urothelial Bladder Carcinoma
Tianjin Medical University Second Hospital
Phase 2 Unknown
NCT05580354 2022-10-14
Safety and Efficacy of BCG Combined With Tislelizumab for BCG-untreated Patients With High-risk Non-muscle Invasive Bladder Cancer
Ruijin Hospital
Phase 4 Unknown
NCT05401279 2022-08-18
Bladder Sparing Treatment of Tislelizumab, Gemcitabine and Cisplatin for Patients With PD-L1 Positive Muscle Invasive Bladder Cancer
RenJi Hospital
Phase 2 Unknown
NCT04922047 2021-06-11
TACBIN-01
RenJi Hospital
Phase 1/2 Unknown